Source: Annual Congress 2012 - Diffuse parenchymal lung disease II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Tomassetti, C. Gurioli, C. Ravaglia, S. Piciucchi, G.L. Casoni, M. Romagnoli, C. Gurioli, V. Poletti (Forli, Italy). The clinical relevance of autoimmunity in idiopathic pulmonary fibrosis. Eur Respir J 2012; 40: Suppl. 56, 3639

Member's Comments

No comment yet.

Related content which might interest you: Evaluating disease severity in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 26 (145) 170051; 10.1183/16000617.0051-2017 Year: 2017 Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis Source: Eur Respir J 2016; 48: 538-552 Year: 2016 Towards a better diagnosis of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 108-113 Year: 2011 The genetic basis of idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1717-1727 Year: 2015 Endotrophin is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Comparison of clinical characteristics and prognosis in patients with idiopathic pulmonary upper lobe predominant pulmonary fibrosis and idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis Source: Eur Respir Rev 2012; 21: 48-56 Year: 2012 Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis Source: Eur Respir J, 50 (1) 1700379; 10.1183/13993003.00379-2017 Year: 2017 Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients Source: Breathe, 16 (1) 190321; 10.1183/20734735.0321-2019 Year: 2020 Potential new biomarkers for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018 Year: 2018 Clinical features and predictive factors for acute exacerbation of idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical aspects of idiopathic pulmonary fibrosis Year: 2007 Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Clinical course of idiopathic pulmonary fibrosis (IPF): Prediction and outcome Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Pathogenesis of idiopathic pulmonary fibrosis: role of neutrophil inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 102s Year: 2006 Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018